neurodegeneration funding
35 open opportunities tagged neurodegeneration, across federal agencies and private foundations. Sorted by deadline.
Addressing Dementia in Tribal and Urban Indian Communities: CAReS Program
This program is intended to support Tribal and Urban Indian communities in strengthening dementia care and services for American Indian and Alaska Native (AI/AN) people.
Review criteria on fileNovel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD).
3 review criteria on fileNovel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD).
3 review criteria on fileDoW Alzheimer’s Transforming Diagnosis Award
Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Diagnosis Award (TrDA) supports non-incremental, solutions-oriented research that reduces or overcomes important barriers to obtaining a diagnosis, meaningful disease monitoring and accurate prognosis.
Review criteria on fileDoW Alzheimer’s Transforming Research Award
Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Research Award (TrRA) supports non-incremental, robust, well-designed research that drives transformative advancements in reducing risk and preventing the development of Alzheimer’s disease and/or Alzheimer's disease related dementias (AD/ADRD).
Review criteria on fileDoW Alzheimer’s Transforming Care Award
Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Care Award (TrCA) supports clinical research or clinical trials evaluating interventions, innovations, and solutions in critical areas for dementia care for individuals with Alzheimer’s disease and Alzheimer’s disease related dementia (AD/ADRD) and…
Review criteria on fileInstitutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
The specific purpose of this Notice of Funding Opportunity (NOFO) is to promote the development of a diverse, interdisciplinary workforce needed to conduct translational research on Alzheimer's disease and Alzheimer's-related dementias from target discovery through clinical development.
7 review criteria on fileSingle Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)
his is a non-competitive funding opportunity intended to fund a single award.
9 review criteria on fileRenewal of the Clinician-Scientists Transdisciplinary Aging Research (Clin-STAR) Coordinating Center (U24 Clinical Trial Not Allowed)
Background Emerging clinicians who recognize the importance of aging within their discipline need essential guidance and resources to become competitive in aging research.
7 review criteria on fileDoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery.
Review criteria on fileDoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies.
Review criteria on fileDoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS).
Review criteria on fileDoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS).
Review criteria on fileCausal Hypotheses on the Oral-Systemic Health Impacts of Human Behaviors among People with Chronic Conditions (U01 Clinical Trial Not Allowed)
6 years.25 billion fewer life years for the United States population.
3 review criteria on fileAlzheimer's Drug-Development Program (U01 Clinical Trial Optional)
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms.
5 review criteria on fileBRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)
The Theories, Models and Methods (TMM) initiative will support the development of computational tools for understanding dynamic brain circuits that are made broadly accessible to the greater research community.
3 review criteria on fileTranslational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) invites applications that combine computational and experimental approaches to enable rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in…
3 review criteria on fileUtilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian…
3 review criteria on fileNIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)
The objective of the NIA Academic Leadership Career Award (K07) is to provide support for established investigators who have the expertise and leadership skills to enhance aging and/or Alzheimer's Disease (AD) and Alzheimers Disease Related Dementias (ADRD)research capacity within their academic institution.
8 review criteria on fileINCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)
The INCLUDE Transformative Research Award Program supports collaborative investigative teams or individual scientists who propose unusually innovative research projects, which, if successful, would have a major impact in understanding the biology of Down syndrome or related co-occurring conditions, or development of new treatments for…
3 review criteria on fileINCLUDE Project: Exploratory/Developmental Research Awards for Down syndrome (R21 Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) invites researchers to submit applications for support of new exploratory and developmental research projects that address important gaps in Down syndrome research.
3 review criteria on fileINCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)
Purpose The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome.
3 review criteria on fileSeamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias…
3 review criteria on fileDoW Parkinson’s, Investigator-Initiated Research Award
Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Investigator-Initiated Research Award (IIRA) supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research.
Review criteria on fileDoW Parkinson’s, Early Investigator Research Award
Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Early Investigator Research Award (EIRA) supports Parkinson’s disease (PD) research for investigators in the early stages of their careers. The FY26 EIRA offers two funding levels, which align to the research career stage of the Principal Investigator (PI).
Review criteria on fileAmyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
C. 360bbb) .
3 review criteria on fileNIA Expanding Research in AD/ADRD (ERA) Postbaccalaureate Research Education Program (R25 Independent Clinical Trial Not Allowed)
This Notice of Funding Opportunity Announcement (NOFO) invites R25 applications to support the development and implementation of research education programs for recent baccalaureates from all backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences.
9 review criteria on fileNIA Expanding Research in AD/ADRD (ERA) Summer Research Education Program (R25 Independent Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) invites R25 applications to support the development and implementation of summer research education programs for high school students, undergraduates, or science teachers from all backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences.
8 review criteria on fileBrightFocus Foundation — Hidden RNA Alterations by Jumping Genes in Alzheimer's Disease
Hidden RNA Alterations by Jumping Genes in Alzheimer's Disease BrightFocus Foundation BrightFocus is a premier funder of groundbreaking research in an urgent effort to discover cures for Alzheimer’s disease, macular degeneration, and glaucoma.
BrightFocus Foundation — Artificial Intelligence-Guided Drug Discovery for Alzheimer's Disease
Artificial Intelligence-Guided Drug Discovery for Alzheimer's Disease BrightFocus Foundation BrightFocus is a premier funder of groundbreaking research in an urgent effort to discover cures for Alzheimer’s disease, macular degeneration, and glaucoma.
BrightFocus Foundation — Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening BrightFocus Foundation BrightFocus is a premier funder of groundbreaking research in an urgent effort to discover cures for Alzheimer’s disease, macular degeneration, and glaucoma. Search Translation EN ES FR DE ID About the Disease What is Glaucoma?
BrightFocus Foundation — The Immune Landscape of the Human Optic Nerve Head
The Immune Landscape of the Human Optic Nerve Head BrightFocus Foundation BrightFocus is a premier funder of groundbreaking research in an urgent effort to discover cures for Alzheimer’s disease, macular degeneration, and glaucoma. Search Translation EN ES FR DE ID About the Disease What is Glaucoma?
BrightFocus Foundation — Spatial Responses to Elevated Pressure in the Human Optic Nerve Head
Spatial Responses to Elevated Pressure in the Human Optic Nerve Head BrightFocus Foundation BrightFocus is a premier funder of groundbreaking research in an urgent effort to discover cures for Alzheimer’s disease, macular degeneration, and glaucoma. Search Translation EN ES FR DE ID About the Disease What is Glaucoma?
BrightFocus Foundation — Activating the Eye’s Own Nitric Oxide to Fight Glaucoma
Activating the Eye’s Own Nitric Oxide to Fight Glaucoma BrightFocus Foundation BrightFocus is a premier funder of groundbreaking research in an urgent effort to discover cures for Alzheimer’s disease, macular degeneration, and glaucoma. Search Translation EN ES FR DE ID About the Disease What is Glaucoma?
Alzheimer's Association — The International Research Grant Program Council
3900 Enter your search Enter your search $ Donate Donate GIVE IN HONOR & MEMORY The International Research Grant Program Council Share or print this page The International Research Grant Program Council The International Research Grant Program (IRGP) Council was formed by the Alzheimer’s Association to assist in crafting requests for…
See which neurodegeneration opportunities fit your work
An account is free and shows the full announcement, the review criteria reviewers score you against, and whether you are actually eligible — including the windows that close before the deadline does.
No card required.